RT Journal Article
T1 The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
A1 Tamma, Pranita D
A1 Rodriguez-Bano, Jesus
K1 ESBLs
K1 carbapenems
K1 cefepime
K1 cephamycins
K1 piperacillin-tazobactam.
AB The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.
YR 2017
FD 2017
LK http://hdl.handle.net/10668/11031
UL http://hdl.handle.net/10668/11031
LA en
DS RISalud
RD Apr 7, 2025